Prospective Grant of Start-Up Exclusive License: Photosensitizing Antibody-Fluorophore Conjugates for Photoimmunotherapy, 18999 [2013-07166]

Download as PDF Federal Register / Vol. 78, No. 60 / Thursday, March 28, 2013 / Notices proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Loan Repayment Program. Date: April 22, 2013. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Sathasiva B. Kandasamy, Ph.D., Scientific Review Officer, Division Of Scientific Review, National Institute Of Child Health And Human Development, 6100 Executive Boulevard, Rockville, Md 20892– 9304, (301) 435–6680, skandasa@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: March 22, 2013. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–07123 Filed 3–27–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Start-Up Exclusive License: Photosensitizing Antibody-Fluorophore Conjugates for Photoimmunotherapy National Institutes of Health, Public Health Service, HHS. AGENCY: mstockstill on DSK4VPTVN1PROD with NOTICES ACTION: Notice. SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide exclusive patent license, to practice the inventions embodied in PCT patent application PCT/US2012/044421, filed June 27, 2012 (HHS Reference# E–205– 2010/2–PCT–01), which is a continuation-in-part of U.S. Application No. 13/180,111 (E–205–2010/1–US–01) which claims priority to U.S. provisional application No. 61/363,079 (E–205–2010/0–US–01), and entitled ‘‘Photosensitizing AntibodyFluorophore Conjugates,’’ to Aspyrian Therapeutics, Inc., a company incorporated under the laws of the State VerDate Mar<15>2010 20:20 Mar 27, 2013 Jkt 229001 of Delaware, having its headquarters in San Diego, California. The United States of America is the assignee of the rights of the above invention. The field of use may be limited to ‘‘use of photosensitizing antibodyfluorophore conjugate by itself for Photoimmunotherapy (PIT), or in combination with cancer therapeutic agents, to treat cancer or pre-cancerous hyperplasia’’, and may be further limited to certain types of cancer and/ or specific platforms. The license will include the priority case US 13/180,111, which is currently licensed to Aspyrian under an exclusive evaluation option license. The exclusive commercialization license proposed in this notice will supersede and replace the exclusive evaluation option license. DATES: Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before April 12, 2013 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Uri Reichman, Ph.D., M.B.A, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 4616; Facsimile: (301) 402–0220; Email: Reichmau@mail.nih.gov. A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the World Intellectual Property Organization. SUPPLEMENTARY INFORMATION: The invention is in the field of Photoimmunotherapy (PIT). More specifically, the invention relates to antibody-fluorophore conjugates where the antibody is specific for cancer cells and the fluorophore is IR700 dye. Binding of such conjugates to targeted cancer cells followed by irradiation with near infrared light (NIR) was shown to kill cancer cells in a highly specific manner. Furthermore, the invention discloses that the therapeutic effect of the PIT conjugate is significantly enhanced by the administration of one or more anti-cancer agents following the irradiation step. This is achieved by the markedly rapid accumulation of the therapeutic agent in the PIT-treated tissue. Also provided in the invention are wearable devices that incorporate NIR light emitting diodes (LEDs) and can be used to activate the PIT conjugates. PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 18999 The prospective exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: March 22, 2013. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2013–07166 Filed 3–27–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY U.S. Customs and Border Protection Accreditation and Approval of SGS North America, Inc., as a Commercial Gauger and Laboratory U.S. Customs and Border Protection, Department of Homeland Security. ACTION: Notice of accreditation and approval of SGS North America, Inc., as a commercial gauger and laboratory. AGENCY: SUMMARY: Notice is hereby given, pursuant to CBP regulations, that SGS North America, Inc., has been approved to gauge and accredited to test petroleum and petroleum products, organic chemicals and vegetable oils for customs purposes for the next three years as of November 1, 2012. DATES: Effective Dates: The accreditation and approval of SGS North America, Inc., as commercial gauger and laboratory became effective on November 1, 2012. The next triennial inspection date will be scheduled for November 2015. FOR FURTHER INFORMATION CONTACT: Approved Gauger and Accredited Laboratories Manager, Laboratories and Scientific Services, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue NW., Suite 1500N, Washington, DC 20229, tel. 202–344–1060. E:\FR\FM\28MRN1.SGM 28MRN1

Agencies

[Federal Register Volume 78, Number 60 (Thursday, March 28, 2013)]
[Notices]
[Page 18999]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07166]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-Up Exclusive License: Photosensitizing 
Antibody-Fluorophore Conjugates for Photoimmunotherapy

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services (HHS), is contemplating the 
grant of a worldwide exclusive patent license, to practice the 
inventions embodied in PCT patent application PCT/US2012/044421, filed 
June 27, 2012 (HHS Reference E-205-2010/2-PCT-01), which is a 
continuation-in-part of U.S. Application No. 13/180,111 (E-205-2010/1-
US-01) which claims priority to U.S. provisional application No. 61/
363,079 (E-205-2010/0-US-01), and entitled ``Photosensitizing Antibody-
Fluorophore Conjugates,'' to Aspyrian Therapeutics, Inc., a company 
incorporated under the laws of the State of Delaware, having its 
headquarters in San Diego, California.
    The United States of America is the assignee of the rights of the 
above invention.
    The field of use may be limited to ``use of photosensitizing 
antibody-fluorophore conjugate by itself for Photoimmunotherapy (PIT), 
or in combination with cancer therapeutic agents, to treat cancer or 
pre-cancerous hyperplasia'', and may be further limited to certain 
types of cancer and/or specific platforms.
    The license will include the priority case US 13/180,111, which is 
currently licensed to Aspyrian under an exclusive evaluation option 
license. The exclusive commercialization license proposed in this 
notice will supersede and replace the exclusive evaluation option 
license.

DATES: Only written comments and/or applications for a license received 
by the NIH Office of Technology Transfer on or before April 12, 2013 
will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Uri Reichman, Ph.D., M.B.A, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4616; 
Facsimile: (301) 402-0220; Email: Reichmau@mail.nih.gov. A signed 
confidentiality nondisclosure agreement will be required to receive 
copies of any patent applications that have not been published or 
issued by the United States Patent and Trademark Office or the World 
Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: The invention is in the field of 
Photoimmunotherapy (PIT). More specifically, the invention relates to 
antibody-fluorophore conjugates where the antibody is specific for 
cancer cells and the fluorophore is IR700 dye. Binding of such 
conjugates to targeted cancer cells followed by irradiation with near 
infrared light (NIR) was shown to kill cancer cells in a highly 
specific manner. Furthermore, the invention discloses that the 
therapeutic effect of the PIT conjugate is significantly enhanced by 
the administration of one or more anti-cancer agents following the 
irradiation step. This is achieved by the markedly rapid accumulation 
of the therapeutic agent in the PIT-treated tissue. Also provided in 
the invention are wearable devices that incorporate NIR light emitting 
diodes (LEDs) and can be used to activate the PIT conjugates.
    The prospective exclusive license will comply with the terms and 
conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive 
license may be granted unless, within fifteen (15) days from the date 
of this published notice, NIH receives written evidence and argument 
that establishes that the grant of the license would not be consistent 
with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 22, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-07166 Filed 3-27-13; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.